Philogen S.p.A.

Equities

PHIL

IT0005373789

Biotechnology & Medical Research

Market Closed - Borsa Italiana Other stock markets 11:44:59 2024-05-03 am EDT			5-day change	1st Jan Change
17.95 ^EUR	+0.56%		-0.83%	-2.97%

Apr. 12	Indices up; Italy, industrial sales down	AN
Apr. 03	Transcript : Philogen S.p.A., 2023 Earnings Call, Apr 03, 2024

Philogen S p A : to attend the Goldman Sachs 45th Annual Global Healthcare Conference in Miami on June 12, 2024.

April 24, 2024 at 08:34 am EDT

2024, Events, Investors

Philogen to attend the Goldman Sachs 45th Annual Global Healthcare Conference in Miami on June 12, 2024.

Apr 24, 2024

The conference provides an opportunity for investors to learn about Philogen's progress and to meet CEO/CSO Prof. Dario Neri through a series of one-on-one meetings.

Prof. Neri will give a presentation on June 12 at 1:20 pm.

Follow the link here for more details.

Attachments

Original Link
Permalink

Disclaimer

Philogen S.p.A. published this content on 24 April 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 April 2024 12:33:10 UTC.

Latest news about Philogen S.p.A.

Indices up; Italy, industrial sales down	Apr. 12	AN
Transcript : Philogen S.p.A., 2023 Earnings Call, Apr 03, 2024	Apr. 03
Philogen reduces loss in 2023; NFP remains positive	Mar. 27	AN
Philogen S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Mib re-emerges in green; Saipem resumes rally	Mar. 07	AN
Futures await lists in red	Feb. 27	AN
Europeans down; Sogefi flies in Piazza Affari.	Feb. 26	AN
Philogen S.p.A. Provides Update on Pre-Planned Interim Analysis of the Phase III FIBROSARC Trial Investigating Onfekafusp Alfa in Patients with First-Line Advanced or Metastatic Soft Tissue Sarcoma	Feb. 20	CI
Mib in the red at 31,600; TIM still on top	Feb. 19	AN
European indexes down; TIM tops Mib	Feb. 19	AN
Futures bullish; PMI data coming in.	Jan. 24	AN
Mib gives ground; Saipem resists declines	Jan. 23	AN
Mib loses 30,000 points; MPS shines	Jan. 17	AN
Mib falls below 30,400; Amplifon tops	Jan. 08	AN
Piazza Affari down slightly; banks on the Mib do well	Jan. 08	AN
Philogen S.P.A. Announces Receipt of the Good Manufacturing Practice Certificate for Its New Production Facility in Rosia (Siena, Italy) by Competent Authorities	Dec. 05	CI
Cucinelli on Mib in December; Philogen, d'Amico and SAES on Mid	Nov. 23	AN
Philogen, net financial position falls in third quarter	Nov. 08	AN
Philogen has purchased 3,300 shares of its own common stock	23-10-23	AN
Transcript : Philogen S.p.A. - Special Call	23-10-18
Philogen purchased 10,400 shares of its own common stock	23-10-17	AN
Philogen S.P.A. and Sun Pharmaceutical Industries Limited Announces Positive Results from the Phase III Pivotal Trial in Patients with Locally Advanced Fully Ressectable Melanoma	23-10-16	CI
Philogen announces positive Phase III results for Nidlegy	23-10-16	AN
Philogen purchased approximately 8,000 shares of its own common stock	23-10-09	AN
Philogen purchased more than 5,400 shares of its own common stock	23-10-02	AN

Chart Philogen S.p.A.

Duration

Period

More charts

Company Profile

Philogen SpA is an Italy-based company, operating in the biotechnology sector. The Company develops products and technologies for the diagnosis and therapy of serious human diseases. It has three anti-cancer antibody derivatives, produced with an in-house industrial process, into Phase I/II clinical studies. The majority of its technologies and products are based on high-affinity human monoclonal antibody fragments. Philogen SpA developed a patented technology, Iterative Colony Filter Screening, for the isolation of monoclonal antibodies, which requires neither immunization nor phage display. The Company's subsidiaries are Philotec, Philomed and Philochem. Philogen SpA is headquartered in Siena, Italy.

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Philogen S.p.A.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

17.95 EUR

Average target price

23.5 EUR

Spread / Average Target

+30.92%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PHILOGEN S.P.A.	-2.97%	779M
REGENERON PHARMACEUTICALS, INC.	+8.96%	105B
VERTEX PHARMACEUTICALS INCORPORATED	-1.43%	104B
ARGENX SE	+4.40%	22.94B
BIONTECH SE	-12.15%	22.34B
GENMAB A/S	-4.36%	19.25B
WUXI APPTEC CO., LTD.	-39.98%	17.08B
BEIGENE, LTD.	-10.04%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+6.79%	14.16B
SAREPTA THERAPEUTICS, INC.	+38.61%	12.63B

Bio Therapeutic Drugs